circadian

ASX / Media Release

19 May 2014

CIRCADIAN APPOINTS CFO AND COMPANY SECRETARY

Circadian Technologies Limited (ASX:CIR) is pleased to announce the appointment of Mr Michael Tonroe to the position of Chief Financial Officer and Company Secretary, effective May 19 2014.

Mr Tonroe joins Circadian with over 20 years experience in finance and company secretarial roles. His most recent role was as Chief Financial Officer of the Australian Synchrotron Company Limited. His previous roles included financial analysis, forecasting, implementing growth plans, fund-raising, board and shareholder reporting.

Mr Tonroe holds a Graduate Degree in Business Studies from Buckingham University and is a Chartered Accountant. He is a Member of the Australian Institute of Company Directors and has previously held board positions at Australian Synchrotron, Sigtec, i-to-i UK Ltd and LBM UK Ltd.

Circadian's Managing Director and CEO, Megan Baldwin, said "Michael brings a wealth of experience in financial management to Circadian. We look forward to drawing on this experience as Circadian continues on its path as a focussed biotechnology company developing eye disease therapies."

Company and media enquiries:
Megan Baldwin
CEO & Managing Director
Circadian Technologies
Tel: +61 (3) 9826 0399
megan.baldwin@circadian.com.au

About Circadian Technologies Limited
Circadian (ASX:CIR; OTCQX:CKDXY) is a biologics drug developer focusing on ophthalmic disease therapies. It controls exclusive worldwide rights to a significant intellectual property portfolio around Vascular Endothelial Growth Factor (VEGF)-C and -D. The applications for the VEGF technology, which functions in regulating blood and lymphatic vessel growth, are substantial and broad. Circadian's internal product development programs are primarily focused on developing OPT-302 (formerly VGX-300, soluble VEGFR-3) for 'back of the eye' disease such as wet age-related macular degeneration (wet AMD). Circadian has also licensed rights to some parts of its intellectual property portfolio for the development of other products to ImClone Systems, a wholly-owned subsidiary of Eli Lilly and Company, including the anti-lymphatic antibody-based drug IMC-3C5 targeting VEGFR-3.